[Analysis of risk factors of urethral stricture and urinary incontinence after transurethral resection of the prostate].

Objective: The purpose of this study was to analyze the risk factors for predicting urethral stricture and urinary incontinence after transurethral resection of the prostate (TURP).

Methods: A retrospective study of 261 patients admitted from October 2018 to October 2022 who received TURP for benign prostatic hyperplasia (BPH) with complete postoperative follow-up data of at least 6 months. Patients were divided into urethral stricture group (n =18), non-urethral stricture group (n =243), urinary incontinence group (n = 12) and non-urethral incontinence group (n = 249) according to the presence of urethral stricture and urinary incontinence.

Efficacy of amisulpride on postoperative nausea and vomiting: a systematic review and meta-analysis.

Aim And Background: Postoperative nausea and vomiting (PONV) remains a significant clinical problem for surgical patients. Amisulpride is a well-studied DD antagonist that has the potential to be used for preventing and treating PONV. Our aim was to assess the efficacy and safety of amisulpride for prevention and treatment of PONV through a systematic review and meta-analysis.

Efficacy of Internet-delivered cognitive-behavioral therapy for the management of chronic pain in children and adolescents: A systematic review and meta-analysis.

Background: Pediatric chronic pain is relatively common in the world. Although cognitive behavior therapy (CBT) has been shown to be efficacious in children and adolescents, it is generally recognized that availability and accessibility of CBT are limited. While Internet-delivered cognitive-behavioral therapy (ICBT) performs better in these areas.

Surgical Training Improves Performance in Minimally Invasive Left Ventricular Assist Device Implantation Without Cardiopulmonary Bypass.

Objective: We introduced a live animal model for training of minimally invasive implantation of a continuous-flow left ventricular assist device (CF-LVAD) without cardiopulmonary bypass for operator's performance improvement.

Design: After watching a videotape of LVAD implantation on the beating heart through the cardiac apex, the surgical team performed implantation of LVADs into 5 pigs during 3 training sessions in a time series. The procedure success rate, operating time, and technical and global performances by self-evaluation and senior evaluation were compared among the sessions.

[Analysis of surgical treatment of coronary artery disease with mitral regurgitation].

Objective: To analyze the effect of combined coronary artery with mitral valve surgery and summarize our clinical experience.

Methods: From August, 2002 to May, 2006, 42 patients underwent combined CABG and mitral valve surgery because of concomitant ischemia myocardium disease and mitral regurgitation (MR) of moderate to severe degree. The etiology of MR was ischemic myocardium disease in 38 (90.

[Administration of sirolimus affects vein graft neointima hyperplasia].

Objective: To investigate the effect of Sirolimus on vein graft neointima hyperplasia via oral administration compared with local delivery, and find out an effective and safe way to provide support for clinical application.

Methods: A rabbit external jugular vein-to-common carotid artery model was established. Twenty-four healthy rabbits were divided into 4 groups at random: blank-control group, F-127 control group, group 3 that received locally applied slow-releasing Sirolimus with F-127, group 4 that received oral Sirolimus (the commercial name Rapamune).

[Local applied slow-releasing rapamycin inhibits neointima hyperplasia in vein graft].

Objective: To investigate whether rapamycin (RPM) can reduce the neointima formation in the autologous vein graft, thus to provide support for its clinical application.

Methods: Twenty-four male rabbits were made external jugular vein-to-common carotid artery models and then were divided into 4 equal groups at random: blank-control group; F-127 control group receiving local application of 0.5 ml 20% F-127 around the vein graft; low-dose RPM group, receiving local application of 0.